アルツハイマー病のような脳アミロイドーシスの分子生物学に関する新しい洞察は,マルチオミックスのアプローチによって達成されました

Lorenzo Campanelli1, Juan M Sendoya2, Scott Brody3

  • 1Laboratory of Brain Aging and Neurodegeneration, Fundación Instituto Leloir, Ciudad Autónoma de Buenos Aires, Argentina.

PloS one
|September 3, 2025
PubMed
まとめ

この研究は,腸内細菌と代謝物質を脳の変化に結びつけることで,ダイエットがアルツハイマー病 (AD) にどのように影響するかを明らかにしています. ネットワーク分析はADの脳-腸軸への免疫系の関与を強調しています.

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260